Maximum quantity allowed is 999
请选择数量
CAS RN: 166518-60-1 | 产品编码: A3594
Avasimibe
×
![]()
×
| 产品编码 | A3594 |
| 纯度/分析方法 | >98.0%(HPLC) |
| 分子式/分子量 | C__2__9H__4__3NO__4S = 501.73 |
| 外观与形状（20°C） | 固体 |
| 储存温度 | 冷藏 (0-10°C) |
| 储存在惰性气体下 | 存放于惰性气体之中 |
| 应避免的情况 | 空气,加热 |
| CAS RN | 166518-60-1 |
| Reaxys-RN | 7608606 |
| MDL编号 | MFCD00934956 |
技术规格
| Appearance | White to Light yellow powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Melting point | 172.0 to 176.0 °C |
| NMR | confirm to structure |
物性（参考值）
| 熔点 | 174 °C |
GHS
相关法规
| RTECS# | CY1482550 |
运输信息
| HS编码* | 2929.90-000 |
应用
Avasimibe: An Orally Bioavailable Inhibitor of ACAT (SOAT)
Acyl-Coenzyme A: Cholesterol Acyltransferase (ACAT, also known as sterol O-acyltransferase or SOAT) is an intracellular enzyme that catalyzes the formation of cholesteryl esters from cholesterol and fatty acyl-CoA. Avasimibe (Cl-1011) is an orally bioavailable inhibitor of ACAT. Animal studies have shown that ACAT inhibitors, including avasimibe, reduce plasma cholesterol levels by suppressing the absorption of dietary cholesterol.1,2) Recently, many studies have suggested that ACAT-1 (SOAT-1) plays a critical role in cancer initiation and progression and is an attractive target for novel anticancer therapy. The inhibitor avasimibe has been shown to have antitumor activity.3,4) (The product is for research purpose only.)
Reference
- 1) Pharmacology of the ACAT inhibitor avasimibe (CI-1011) (a review)
- 2) Inhibitors of acyl-coenzyme A: Cholesterol acyltransferase (a review)
- 3) Targeting human Acyl-CoA:cholesterol acyltransferase as dual viral and T cell metabolic checkpoint
- 4) Targeting sterol-O-acyltransferase 1 to disrupt cholesterol metabolism for cancer therapy (a review)
产品文档 (部分产品的分析图谱无法提供，敬请谅解。)
化学品安全说明书(SDS)
请选择语言。
如需更多帮助，请联系我 们。
技术规格
CoA及其他文档
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
示例 CoA
可下载CoA示例。注：该示例不一定是最新批次的CoA。
目前没有该产品的 CoA 示例。
分析图谱
请输入批号
批号输入有误。请输入中横线前的4-5个字母数字字符。
很抱歉，您搜索的分析图谱无法提供。